Trial Profile

A phase 1 study of GDA-201 for treatment of non-Hodgkin lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GDA 201 (Primary)
Indications Non-Hodgkin's lymphoma
Focus Therapeutic Use

Most Recent Events

23 Feb 2024 Results published in the Media Release, According to Gamida-Cell Media Release, data from this trial presented at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). The hybrid meetings take place February 21-24 virtually and in person in San Antonio, Texas.
21 Aug 2023 New trial record
14 Aug 2023 According to Gamida cell media release, data are expected in the first quarter of 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com